 | • レポートコード：MRC2-11QY12225 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はホルモン抵抗性前立腺がんのグローバル市場について調査・分析したレポートです。種類別（化学療法、ホルモン療法、免疫療法、放射線療法、外科）市場規模、用途別（病院、外来手術センター、専門クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ホルモン抵抗性前立腺がんの競争状況、市場シェア ・世界のホルモン抵抗性前立腺がん市場：種類別市場規模 2015年-2020年（化学療法、ホルモン療法、免疫療法、放射線療法、外科） ・世界のホルモン抵抗性前立腺がん市場：種類別市場規模予測 2021年-2026年（化学療法、ホルモン療法、免疫療法、放射線療法、外科） ・世界のホルモン抵抗性前立腺がん市場：用途別市場規模 2015年-2020年（病院、外来手術センター、専門クリニック） ・世界のホルモン抵抗性前立腺がん市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター、専門クリニック） ・北米のホルモン抵抗性前立腺がん市場分析：米国、カナダ ・ヨーロッパのホルモン抵抗性前立腺がん市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのホルモン抵抗性前立腺がん市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のホルモン抵抗性前立腺がん市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのホルモン抵抗性前立腺がん市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Astellas Inc、Sanofi S.A、Dendreon Corporation, Bayer AG、Johnson & Johnson ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer Market
The global Hormone Refractory Prostate Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hormone Refractory Prostate Cancer Scope and Market Size
Hormone Refractory Prostate Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
…
Market segment by Type, the product can be split into
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
1.4 Market by Type
1.4.1 Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Hormonal Therapy
1.4.4 Immunotherapy
1.4.5 Radiation Therapy
1.4.6 Surgery
1.5 Market by Application
1.5.1 Global Hormone Refractory Prostate Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer Market Perspective (2015-2026)
2.2 Global Hormone Refractory Prostate Cancer Growth Trends by Regions
2.2.1 Hormone Refractory Prostate Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hormone Refractory Prostate Cancer Historic Market Share by Regions (2015-2020)
2.2.3 Hormone Refractory Prostate Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hormone Refractory Prostate Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key Hormone Refractory Prostate Cancer Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer Players by Market Size
3.1.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue (2015-2020)
3.1.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hormone Refractory Prostate Cancer Market Concentration Ratio
3.2.1 Global Hormone Refractory Prostate Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer Revenue in 2019
3.3 Hormone Refractory Prostate Cancer Key Players Head office and Area Served
3.4 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
3.5 Date of Enter into Hormone Refractory Prostate Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2015-2020)
4.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
5.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size (2015-2020)
6.2 Hormone Refractory Prostate Cancer Key Players in North America (2019-2020)
6.3 North America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
6.4 North America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size (2015-2020)
7.2 Hormone Refractory Prostate Cancer Key Players in Europe (2019-2020)
7.3 Europe Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
7.4 Europe Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
8 China
8.1 China Hormone Refractory Prostate Cancer Market Size (2015-2020)
8.2 Hormone Refractory Prostate Cancer Key Players in China (2019-2020)
8.3 China Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
8.4 China Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hormone Refractory Prostate Cancer Market Size (2015-2020)
9.2 Hormone Refractory Prostate Cancer Key Players in Japan (2019-2020)
9.3 Japan Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
9.4 Japan Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hormone Refractory Prostate Cancer Market Size (2015-2020)
10.2 Hormone Refractory Prostate Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
11 India
11.1 India Hormone Refractory Prostate Cancer Market Size (2015-2020)
11.2 Hormone Refractory Prostate Cancer Key Players in India (2019-2020)
11.3 India Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
11.4 India Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hormone Refractory Prostate Cancer Market Size (2015-2020)
12.2 Hormone Refractory Prostate Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
12.4 Central & South America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Astellas Inc
13.1.1 Astellas Inc Company Details
13.1.2 Astellas Inc Business Overview
13.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
13.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2015-2020))
13.1.5 Astellas Inc Recent Development
13.2 Sanofi S.A
13.2.1 Sanofi S.A Company Details
13.2.2 Sanofi S.A Business Overview
13.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
13.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.2.5 Sanofi S.A Recent Development
13.3 Dendreon Corporation, Bayer AG
13.3.1 Dendreon Corporation, Bayer AG Company Details
13.3.2 Dendreon Corporation, Bayer AG Business Overview
13.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
13.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.3.5 Dendreon Corporation, Bayer AG Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
13.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hormone Refractory Prostate Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
Table 3. Ranking of Global Top Hormone Refractory Prostate Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Hormonal Therapy
Table 7. Key Players of Immunotherapy
Table 8. Key Players of Radiation Therapy
Table 9. Key Players of Surgery
Table 10. Global Hormone Refractory Prostate Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Hormone Refractory Prostate Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Hormone Refractory Prostate Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Hormone Refractory Prostate Cancer Market Share by Regions (2015-2020)
Table 14. Global Hormone Refractory Prostate Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Hormone Refractory Prostate Cancer Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Hormone Refractory Prostate Cancer Market Growth Strategy
Table 20. Main Points Interviewed from Key Hormone Refractory Prostate Cancer Players
Table 21. Global Hormone Refractory Prostate Cancer Revenue by Players (2015-2020) (Million US$)
Table 22. Global Hormone Refractory Prostate Cancer Market Share by Players (2015-2020)
Table 23. Global Top Hormone Refractory Prostate Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer as of 2019)
Table 24. Global Hormone Refractory Prostate Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Hormone Refractory Prostate Cancer Product Solution and Service
Table 27. Date of Enter into Hormone Refractory Prostate Cancer Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 30. Global Hormone Refractory Prostate Cancer Market Size Share by Type (2015-2020)
Table 31. Global Hormone Refractory Prostate Cancer Revenue Market Share by Type (2021-2026)
Table 32. Global Hormone Refractory Prostate Cancer Market Size Share by Application (2015-2020)
Table 33. Global Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 34. Global Hormone Refractory Prostate Cancer Market Size Share by Application (2021-2026)
Table 35. North America Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 37. North America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 38. North America Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 39. North America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 40. North America Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 41. Europe Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 43. Europe Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 45. Europe Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 47. China Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 48. China Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 49. China Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 50. China Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 51. China Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 52. China Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 53. Japan Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 55. Japan Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 57. Japan Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 61. Southeast Asia Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 63. Southeast Asia Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 65. India Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 66. India Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 67. India Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 68. India Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 69. India Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 70. India Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Hormone Refractory Prostate Cancer Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Hormone Refractory Prostate Cancer Market Share (2019-2020)
Table 73. Central & South America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Hormone Refractory Prostate Cancer Market Share by Type (2015-2020)
Table 75. Central & South America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Hormone Refractory Prostate Cancer Market Share by Application (2015-2020)
Table 77. Astellas Inc Company Details
Table 78. Astellas Inc Business Overview
Table 79. Astellas Inc Product
Table 80. Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2015-2020) (Million US$)
Table 81. Astellas Inc Recent Development
Table 82. Sanofi S.A Company Details
Table 83. Sanofi S.A Business Overview
Table 84. Sanofi S.A Product
Table 85. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2015-2020) (Million US$)
Table 86. Sanofi S.A Recent Development
Table 87. Dendreon Corporation, Bayer AG Company Details
Table 88. Dendreon Corporation, Bayer AG Business Overview
Table 89. Dendreon Corporation, Bayer AG Product
Table 90. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2015-2020) (Million US$)
Table 91. Dendreon Corporation, Bayer AG Recent Development
Table 92. Johnson & Johnson Company Details
Table 93. Johnson & Johnson Business Overview
Table 94. Johnson & Johnson Product
Table 95. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2015-2020) (Million US$)
Table 96. Johnson & Johnson Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hormone Refractory Prostate Cancer Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Hormonal Therapy Features
Figure 4. Immunotherapy Features
Figure 5. Radiation Therapy Features
Figure 6. Surgery Features
Figure 7. Global Hormone Refractory Prostate Cancer Market Share by Application: 2020 VS 2026
Figure 8. Hospitals Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Hormone Refractory Prostate Cancer Report Years Considered
Figure 12. Global Hormone Refractory Prostate Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Hormone Refractory Prostate Cancer Market Share by Regions: 2020 VS 2026
Figure 14. Global Hormone Refractory Prostate Cancer Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Hormone Refractory Prostate Cancer Market Share by Players in 2019
Figure 17. Global Top Hormone Refractory Prostate Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Prostate Cancer as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer Revenue in 2019
Figure 19. North America Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Hormone Refractory Prostate Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
前立腺がんの世界市場（～2026年） Prostate cancer is cancer that occurs in the prostate. Market Analysis and Insights: Global Prostate Cancer Market The global Prostate Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Prostate Cancer Scope and Ma…- 去勢抵抗性前立腺がん治療の世界市場（～2026年） Prostate cancer can be defined as it is a form of cancer that develops into male reproductive system. Most of the prostate cancer are slow growing and stable but sometimes it can spread from prostate (gland) to other part of body such as bone and lymph node. Initially prostate cancer does not pose a…
- 前立腺がん治療の世界市場（～2026年） Prostate cancer is the most common cancer among men, the key risk factors for prostate cancer development is being old age, genetic, obesity and race. Market Analysis and Insights: Global Prostate Cancer Treatment Market The global Prostate Cancer Treatment market size is projected to reach US$ XX m…
- 前立腺がん治療薬の世界市場（～2026年） Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise…
- 前立腺がんバイオマーカーの世界市場（～2026年） Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. The prostate cancer biomarker market is expected to witness a fast growth owing to rising prevalence of prostate cancer. Market Analysis and Insights: Global Prostate Cancer Biomarker Market The gl…